Inovio Biomedical Corporation Provides Updated Interim Data on Phase I/II Clinical Study of Electroporation-Delivered Prostate Cancer DNA Vaccine at American Society of Gene Therapy Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that Dr. Christian H. Ottensmeier, MD, PhD, Cancer Research UK Senior Clinical Research Fellow at the University of Southampton, presented updated interim data from a clinical study of an experimental DNA-based prostate cancer vaccine at the American Society of Gene Therapy 11th Annual meeting in Boston, May 28 – June 1. The data reaffirms that, post-treatment, this therapy has proven to be safe and well-tolerated. Additional testing has further validated higher levels of antibody and anti-DOM CD4 responses achieved in patients treated using electroporation.